Texas A&M Football

Ask Liucci: Touchdown Jesus looking down on Ags vs. Irish & more

With the "Word of Life" mural (AKA "Touchdown Jesus") as part of the backdrop, No. 16 Texas A&M will face No. 8 Notre Dame in South Bend on Saturday night. Before heading north, Billy Liucci tackles another round of subscriber questions to get ready for the primetime matchup.
By Billy Liucci
September 9, 2025
3.6k Views
Discuss
Story Poster

Richard Zane: True or false: Between the two quarterbacks, CJ Carr will be under more pressure to win Saturday as a quarterback in a must-win game and his first-ever start at home.

Billy Liucci: I do think CJ Carr is under more pressure. They're 0-1, and CJ Carr had an extended fall camp battle with Kenny Minchey. That was a pretty competitive battle by all accounts.

To watch this video, you must be a TexAgs Premium subscriber.
Try Premium for $1
See Subscription Benefits
Trial only available to users who have never subscribed or participated in a previous trial
Discuss
Tags
Collin Klein Mike Elko Sean Porter Marcus Freeman Steve Sarkisian Ask Liucci Will Howard Quinshon Judkins Arch Manning Garrett Nussmeier Jeremiyah Love Jadarian Price
Show All
Jeremiah Smith CJ Carr John Mateer Kenny Minchey Texas A&M at Notre Dame Reuben Fatheree II Bryce Anderson Trey Zuhn III Le'Veon Moss Dalton Brooks Marcel Reed KC Concepcion Taurean York Mario Craver Marcus Ratcliffe Terry Bussey Ashton Bethel-Roman Will Lee III Scooby Williams Cashius Howell Football Texas A&M Louisiana Tech Oklahoma Texas LSU Notre Dame Clemson Miami Michigan Troy 2025
SPONSORED BY
Maroon U
More Football
See All →
Defense in Review feat. Sean Porter: Texas A&M 44, Utah State 22
By Billy Liucci
B-Team: Winners and losers in CFB, best smells in sports & more
By Ryan Brauninger
A&M's new-look receiving corps expect man-to-man coverage vs. Irish
By Olin Buchanan
Presenting Texas Aggies United’s Bad Tigers Sweepstakes!
By Texas Aggies United
 
×
subscribe Verify your student status
See Subscription Benefits
Trial only available to users who have never subscribed or participated in a previous trial.